Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Kamada Ltd. is a biopharmaceutical company focused on the development, manufacturing, and commercialization of plasma‑derived protein therapeutics. The company operates within the biopharmaceutical and plasma‑derived medicines industries, with a primary emphasis on immune globulins and specialty biologics used to treat rare, chronic, and life‑threatening conditions. Its core revenue drivers are proprietary plasma‑derived products and contract manufacturing services for third‑party pharmaceutical companies.
Kamada’s key products include GLASSIA (alpha‑1 antitrypsin for AAT deficiency) and KEDRAB (rabies immune globulin), which are marketed primarily in the United States. The company is positioned as a fully integrated plasma‑derived therapeutics provider with in‑house capabilities spanning development, regulatory approval, manufacturing, and commercialization. Founded in 1990 in Israel, Kamada evolved from a plasma fractionation specialist into a commercial-stage biopharmaceutical company following U.S. FDA approvals of its lead products in the 2010s.
Business Operations
Kamada operates through two principal business activities: proprietary product sales and contract manufacturing of plasma‑derived proteins. Revenue is generated primarily from sales of GLASSIA and KEDRAB in the U.S. market, alongside long‑term manufacturing agreements with global pharmaceutical partners. The company maintains FDA‑approved manufacturing facilities and controls key purification and fractionation technologies used in plasma processing.
Operations are conducted through the parent company and its U.S. subsidiary, Kamada Inc., which oversees commercialization and regulatory activities in the United States. Kamada does not historically own plasma collection centers and relies on third‑party plasma suppliers, though it has disclosed initiatives to enhance supply chain resilience. The company’s manufacturing infrastructure supports both internal products and external customer programs under multi‑year agreements.
Strategic Position & Investments
Kamada’s strategy centers on expanding its commercial portfolio, maximizing utilization of its manufacturing capacity, and pursuing lifecycle extensions and label expansions for existing products. Growth initiatives include increasing penetration of KEDRAB in the U.S. rabies post‑exposure prophylaxis market and exploring additional plasma‑derived indications leveraging its fractionation platform.
The company has made targeted investments to upgrade manufacturing capabilities and meet evolving regulatory standards, supporting both proprietary products and third‑party contracts. Kamada has not completed large transformative acquisitions in recent years; publicly available sources indicate a focus on organic growth and selective collaborations rather than broad M&A activity. Data on emerging technologies beyond plasma‑derived biologics is limited, and information on diversification into non‑plasma modalities is inconclusive based on available public sources.
Geographic Footprint
Kamada is headquartered in Israel, where its primary manufacturing and research facilities are located. The company’s most significant commercial presence is in the United States, which represents its largest revenue‑generating market due to FDA‑approved products and established reimbursement pathways.
Beyond Israel and the United States, Kamada maintains international exposure through distribution agreements and contract manufacturing relationships that extend into Europe and other global markets. While sales outside the U.S. are comparatively smaller, the company’s regulatory approvals and manufacturing certifications enable participation in multiple international markets.
Leadership & Governance
Kamada is led by an executive team with experience in biopharmaceutical development, manufacturing, and commercialization. The leadership emphasizes disciplined capital allocation, regulatory compliance, and long‑term value creation through sustainable biologics manufacturing.
Key executives include:
- Amir London – Chief Executive Officer
- Amir Salzman – Chief Financial Officer
- David Tsur – Founder (role historical; current operational involvement is limited)
Public disclosures consistently identify Mr. London as the driving force behind Kamada’s current strategic direction, focusing on operational efficiency, commercial execution in the U.S., and expansion of manufacturing partnerships. Information on additional executive officers varies across filings; data inconclusive based on available public sources.